Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 81

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 81
---
 and September 30, 2024 are related to our license agreement with Organon to commercialize XACIATO. From and after April 1, 2024, any revenue we recognize under such license agreement will be recognized as non-cash royalty revenue. See "—Financial Overview—Revenue," above for information. 

General and administrative expenses

For each of the nine months ended September 30, 2025 and 2024, G&A expenses were approximately $7.2 million. The current period's G&A expenses include decreases in stock-based compensation expense and personnel costs, offset by increases in professional services, general corporate overhead, and commercial-readiness expenses driven by execution against our expanded business strategy.

Research and development expenses

The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars and percentage:

39

Nine Months EndedSeptember 30,Change20252024$%Direct program costs:Ovaprene (1)$4,270,154 $7,103,894 $(2,833,740)(40)%Sildenafil Cream (2)678,813 1,105,605 (426,792)(39)%Other advanced clinical stage programs (1)2,165,918 1,009,655 1,156,263 115 %Phase 1 and Phase 1-ready clinical stage programs (1)1,394,982 526,291 868,691 165 %Preclinical stage programs (1)4,878,104 3,232,899 1,645,205 51 %Other development programs— 24,132 (24,132)(100)%Contra R&D expenses (3)(10,713,647)(5,799,795)(4,913,852)85 %Total direct program costs2,674,324 7,202,681 (4,528,357)(63)%Indirect costs:Personnel-related (including stock-based compensation)3,869,767 4,394,329 (524,562)(12)%Outside services (including consulting)21,130 543 20,587 3791 %Facilities-related (including depreciation)55,391 60,344 (4,953)(8)%Other indirect R&D costs161,523 157,526 3,997 3 %Contra R&D expenses(1,880,824)(